PAST, PRESENT AND FUTURE OF REMDESIVIR—OVERVIEW OF A MOST POPULAR ANTIVIRAL IN RECENT TIMES


PAST, PRESENT AND FUTURE OF REMDESIVIR—OVERVIEW OF A MOST POPULAR ANTIVIRAL IN RECENT TIMES


DWAIPAYAN SARATHI CHAKRABORTY*, SHOUVIK CHOUDHURY

REGISTRAR, DEPARTMENT OF CARDIOLOGY, BELLE VUE CLINIC


Journal of Pharmaceutical Research and Reviews

Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734™) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence
about the antiviral effects of remdesivir against to accumulate before the clinical trials are concluded. It is imperative for public health practitioners and the One Health community to stay up to date on the most promising potential therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize the knowledge to date about remdesivir as a therapeutic option for coronaviruses, with a special focus on information relevant to the One Health community


Keywords: REMDESIVIR, COVID-19, Review

Free Full-text PDF


How to cite this article:

DWAIPAYAN SARATHI CHAKRABORTY, SHOUVIK CHOUDHURY. PAST, PRESENT AND FUTURE OF REMDESIVIR—OVERVIEW OF A MOST POPULAR ANTIVIRAL IN RECENT TIMES. Journal of Pharmaceutical Research and Reviews, 2020; 4:20


References:

1. Center for Health Security. The characteristics of pandemic pathogens.cited Mar 4, 2019. Available from:http://www.centerforhealth security.org/our-work/pubs_archive/pubs-pdfs/2018/180510-pandemic-pathogens-report.pdf.
2. R.N. Kirchdoerfer, A.B. Ward, Structure of the SARS-CoV nsp12 polymerase boundto nsp7 and nsp8 co-factors, Nat. Commun. 10 (1) (2019) 2342, https://doi.org/10.1038/s41467-019-10280-3.
3. Cj G, Ep T, Jy F, et al. The antiviral compound remdesivir potently inhibits RNAdependentRNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020. https://doi.org/10.1074/jbc.ac120.013056.
4. “Summary on Compassionate Use: Remdesivir Gilead”(https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf) (PDF). European Medicines Agency. Retrieved 1 May 2020.
5. “COVID-19 interactions” (https://www.covid19-druginteractions.org/).University of Liverpool.Retrieved 28 April 2020.
6. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531:381–5.
7. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017;9 pii: eaal3653. doi: 10.1126/scitranslmed.aal3653 .
8. T. P. Sheahan et al., Comparative therapeutic efficacy of remdesivir and combinationlopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 222 (2020).
9. Lo MK, Feldmann F, Gary JM, Jordan R,et al. Sci Transl Med. 2019 May 29;11(494). pii: eaau9242. doi: 10.1126/scitranslmed.aau9242.
10. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeuticefficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016;531:381–5. doi: 10.1038/nature17180 .
11. Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, et al.GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.ci Rep 2017;7:43395. doi: 10.1038/srep43395.
12. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, et al. Late Ebola virusrelapse causing meningoencephalitis: a case report. Lancet 2016;338:498–503.doi: 10.1016/S0140- 6736(16)30386- 5 .
13. Preidt R (29 June 2017). “Experimental Drug Shows Promise Against Dangerous Viruses:Medicine worked in lab tests against germs that cause SARS and MERS infections” (https://web.archive.org/web/20170728083042/https://medlineplus.gov/news/fullstory_166953.html). Archivedfrom the original (https://medlineplus.gov/news/fullstory_166953.html) on 28 July 2017.
14. Cihlar T (20 October 2015). “Discovery and Development of GS-5734, a Novel NucleotideProdrug with Broad Spectrum Anti-Filovirus Activity” (http://www.jpeocbd.osd.mil/Packs/DocHandl er.ashx%3FDocID%3D700&ved=0ahUKEwjEMD29LTQAhUMlJQKHZc1Ar4QFgh9MBI&usg=AFQjCNGCWr-rWuTyEhr1EfI3pL_T838oqA&sig2=rzvoYXRwM23Oc5aXyAKuwg). FANG-WHOWorkshop. Fort Detrick, MD: Gilead Sciences.
15. Warren T, Jordan R, Lo M, Soloveva V, Ray A, Bannister R, et al. (Fall 2015). “NucleotideProdrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete TherapeuticProtection Against the Development of Ebola Virus Disease (EVD) in Infected Non-humanPrimates”.
16. Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, et al. (July 2016). “Late Ebola virus relapse causing meningoencephalitis: a case report” (https://www.ncbi.nlm.nih.gov/pmc/articles/P MC4967715). Lancet. 388 (10043): 498–503. doi:10.1016/S0140-6736(16)30386-5 (https://doi.org/10.1016%2FS0140-6736%2816%2930386-5). PMC 4967715 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967715). PMID 27209148 (https://pubmed.ncbi.nlm.nih.gov/27209148).
17. Dwyer C (27 November 2018). “Ebola Treatment Trials Launched In Democratic Republic Of TheCongo Amid Outbreak” (https://www.npr.org/2018/11/27/670913385/ebola-treatment-trials-launched-in-democratic-republic-of-the-congo-amid-outbrea). National Public Radio. Retrieved 28 May2019.
18. McNeil DG (12 August 2019). “A Cure for Ebola? Two New Treatments Prove Highly Effective in Congo” (https://www.nytimes.com/2019/08/12/health/ebola-outbreak-cure.html). The New YorkTimes. Retrieved 13 August 2019.
19. Molteni M (12 August 2019). “Ebola is Now Curable. Here’s How The New Treatments Work” (https://www.wired.com/story/ebola-is-now-curable-heres-how-the-new-treatments-work/). Wired.Retrieved 13 August 2019.
20. M S, D Le, D Rt, et al. A randomized, controlled trial of Ebola virus disease therapeutics.The New England journal of medicine 2019;381(24):2293–303.
21. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. April 2020. doi:10.1016/s0140-6736(20)31022-9
22. “Frequently Asked Questions on the Emergency Use Authorization for Remdesivir for CertainHospitalized COVID‐19 Patients” (https://www.fda.gov/media